

# PRODUCT INFORMATION




## Pelitinib

Item No. 15627

**CAS Registry No.:** 257933-82-7  
**Formal Name:** N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2E-butenamide

**Synonym:** EKB-569  
**MF:** C<sub>24</sub>H<sub>23</sub>ClFN<sub>5</sub>O<sub>2</sub>  
**FW:** 467.9  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 209, 260, 283 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Pelitinib is supplied as a crystalline solid. A stock solution may be made by dissolving the pelitinib in the solvent of choice, which should be purged with an inert gas. Pelitinib is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of pelitinib in these solvents is approximately 10 and 20 mg/ml, respectively.

Pelitinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, pelitinib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Pelitinib has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Pelitinib is a cyanoquinoline that irreversibly inhibits the EGFR receptor tyrosine kinase (IC<sub>50</sub> = 39 nM).<sup>1</sup> It inhibits HER2 with a much weaker potency (IC<sub>50</sub> = 1.2 μM).<sup>1</sup> By disrupting Akt and MAPK pathways, pelitinib can induce apoptosis and suppress the growth of tumor cell lines, displaying particularly strong efficacy against hepatocellular carcinoma cells (IC<sub>50</sub>s = ~2 μM).<sup>2</sup>

### References

1. Arkin, M. and Moasser, M.M. HER2 directed small molecule antagonists. *Curr. Opin. Investig. Drugs* **9**(12), 1264-1276 (2008).
2. Kim, H. and Lim, H.Y. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. *J. Korean Med. Sci.* **26**(12), 1563-1568 (2011).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM